Avadel Pharmaceuticals PLC - Asset Resilience Ratio
Avadel Pharmaceuticals PLC (AVDL) has an Asset Resilience Ratio of 5.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore AVDL total asset value for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Avadel Pharmaceuticals PLC's Asset Resilience Ratio has changed over time. See Avadel Pharmaceuticals PLC balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Avadel Pharmaceuticals PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AVDL market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.76 Million | 5.9% |
| Total Liquid Assets | $11.76 Million | 5.90% |
Asset Resilience Insights
- Limited Liquidity: Avadel Pharmaceuticals PLC maintains only 5.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Avadel Pharmaceuticals PLC Industry Peers by Asset Resilience Ratio
Compare Avadel Pharmaceuticals PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
Annual Asset Resilience Ratio for Avadel Pharmaceuticals PLC (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Avadel Pharmaceuticals PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.64% | $22.41 Million | $164.24 Million | -31.25pp |
| 2023-12-31 | 44.90% | $73.94 Million | $164.70 Million | +27.94pp |
| 2022-12-31 | 16.96% | $22.52 Million | $132.78 Million | -26.12pp |
| 2021-12-31 | 43.08% | $106.51 Million | $247.26 Million | -4.95pp |
| 2020-12-31 | 48.03% | $149.68 Million | $311.64 Million | +12.12pp |
| 2019-12-31 | 35.91% | $54.38 Million | $151.44 Million | -11.69pp |
| 2018-12-31 | 47.60% | $90.59 Million | $190.30 Million | +16.86pp |
| 2017-12-31 | 30.75% | $77.51 Million | $252.11 Million | -16.09pp |
| 2016-12-31 | 46.84% | $114.98 Million | $245.48 Million | +9.75pp |
| 2015-12-31 | 37.09% | $79.74 Million | $214.98 Million | +6.63pp |
| 2014-12-31 | 30.47% | $53.07 Million | $174.21 Million | +30.12pp |
| 2013-12-31 | 0.34% | $401.00K | $116.25 Million | -5.12pp |
| 2012-12-31 | 5.47% | $6.41 Million | $117.31 Million | -24.84pp |
| 2011-12-31 | 30.31% | $21.04 Million | $69.40 Million | -0.73pp |
| 2010-12-31 | 31.04% | $23.16 Million | $74.61 Million | -6.45pp |
| 2009-12-31 | 37.49% | $35.35 Million | $94.30 Million | +26.54pp |
| 2008-12-31 | 10.95% | $10.06 Million | $91.86 Million | -3.60pp |
| 2007-12-31 | 14.55% | $14.75 Million | $101.40 Million | +5.02pp |
| 2006-12-31 | 9.53% | $10.94 Million | $114.89 Million | -57.03pp |
| 2005-12-31 | 66.55% | $82.76 Million | $124.35 Million | -2.66pp |
| 2004-12-31 | 69.22% | $100.78 Million | $145.61 Million | -15.98pp |
| 2003-12-31 | 85.20% | $108.42 Million | $127.25 Million | -- |
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more